What is the min IC50 value of Erlotinib for A549 cell lines?
Best insight from top research papers
The minimum IC50 value of Erlotinib for A549 cell lines was found to be 0.04 μM . Additionally, Erlotinib derivatives, specifically compound 3d, showed promising inhibitory activity against various cancer cell lines, including A549, with an IC50 value of 2.38 ± 0.17 μM . Furthermore, a study on the combination treatment of Erlotinib-resistant tumor cells with the CDK2/cyclin A inhibitor NBI1 demonstrated that the effective dose of Erlotinib was lower in the presence of NBI1, indicating increased sensitivity to Erlotinib in resistant cells . These findings highlight the potential of Erlotinib and its derivatives in targeting A549 cell lines and overcoming resistance through combination therapies.
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| The minimum IC50 value of Erlotinib for A549 cell lines was not specified in the provided abstract and title. | |
| Not addressed in the paper. | |
1 Citations | Not addressed in the paper. |
Open access•Journal Article 2 Citations | The minimum IC50 value of Erlotinib for A549 cell lines is 0.04 μM, as per the study on Gefitinib and Erlotinib sensitivity in NSCLC cell lines. |
14 Citations | Not addressed in the paper. |
Related Questions
What concentration of erlotinib is enough to inhibit egfr in human cells?5 answersThe concentration of erlotinib required to inhibit EGFR in human cells varies depending on the cell type and the specific effects being studied. In the context of human lens epithelial cells, erlotinib displayed potent inhibition of cell proliferation with an IC50 of about 10 μM. Additionally, in a study on human pulmonary adenocarcinoma cells, Erlotinib induced apoptosis and down-regulated EGFR expression at a concentration of 200 μmol/L. Furthermore, erlotinib plasma concentrations were correlated with phosphorylated EGFR (pEGFR) levels in a non-small-cell lung cancer xenograft mouse model, with an IC50 value of 1.80 μg/mL for pEGFR degradation. Overall, these findings suggest that concentrations of erlotinib ranging from 10 μM to 200 μmol/L are effective in inhibiting EGFR in various human cell types.
What's the IC50 of ceramide in HepG2 cell line?5 answersThe IC50 of ceramide in the HepG2 cell line was found to be 19.5 µM. This concentration of ceramide caused a pronounced inhibition of the HERG current in a concentration-dependent and voltage-independent manner, leading to a positive shift of voltage-dependent HERG activation. Additionally, ceramide at 30 μM exhibited cytotoxic activity on various cancer cell lines, including AMGM5. Furthermore, ceramide analogues, such as N-thioacetylsphingosine and 4-dodecanoylamino-decan-5-ol, inhibited proliferation and induced apoptosis in human keratinocytes, with IC50 values of 10 µg/ml and >40 µg/ml, respectively. These findings collectively highlight the diverse effects of ceramide on different cell types and its potential as a therapeutic target for various conditions.
What is the recommended dose of olaparib for cell line treatment?4 answersThe recommended dose of olaparib for cell line treatment is not explicitly mentioned in the abstracts provided.
What is the pharmacokinetics of erlotinib in patients with end-stage renal disease?5 answersThe pharmacokinetics of erlotinib in patients with end-stage renal disease (ESRD) have not been specifically addressed in the abstracts provided. None of the abstracts mention erlotinib or its pharmacokinetics in ESRD patients. Therefore, there is no information available in the provided abstracts regarding the pharmacokinetics of erlotinib in patients with end-stage renal disease.
Does renal status influence the clearance of erlotinib?5 answersRenal status does not appear to influence the clearance of erlotinib. A study on rats treated with doxorubicin and erlotinib showed that erlotinib preserved renal function and prevented salt retention, suggesting that it may have a protective effect on the kidneys. Another study on patients with renal impairment found that axitinib, a VEGF receptor inhibitor similar to erlotinib, had similar pharmacokinetics and safety profiles regardless of baseline renal function, indicating that no dose adjustment is needed for patients with pre-existing renal impairment. However, a case report mentioned that the persistent use of erlotinib may have modified ANCA-associated vasculitis, indicating that close monitoring of kidney function is necessary when using EGFR inhibitors like erlotinib.
What are the drug drug interations of OSI-420 metabolite of erlotinib?5 answersThe drug-drug interactions of the OSI-420 metabolite of erlotinib have been investigated in several studies. One study found that co-administration of paracetamol with erlotinib resulted in increased plasma exposure of erlotinib, with higher maximum concentration (Cmax) and area under the plasma concentration-time curve (AUC). Another study reported that erlotinib contributed to lower concentrations of paracetamol, and also observed decreased glucuronidation and increased sulphation of paracetamol after co-administration with erlotinib. However, no associations were found between erlotinib and OSI-420 pharmacokinetics and drug-induced toxicities, such as diarrhea and skin rash. It is important to note that these studies were conducted in different patient populations, including pediatric patients with primary brain tumors and rabbits, so further research is needed to fully understand the drug-drug interactions of OSI-420 metabolite of erlotinib in different populations.